Abstract:Abstract Background On-target off-tumor toxicity impedes the clinical application of chimeric antigen receptor-modified T cells (CAR-T cells) in the treatment of solid tumors. Previous reports proved that the combinatorial antigen recognition strategy could improve the safety profile of CAR-T cells by targeting two different tumor-associated antigens (TAAs), one as a CAR-T targeted antigen and the other as a chimeric costimulatory receptor (CCR) ligand. The programmed death-ligand 1 (PD-L1, also known as B7-H1) is preferentially overexpressed on multiple tumors, it will be highly interesting to explore the potential of PD-L1 as a universal target for designing CCR. Methods A novel dual-targeted CAR, which is composed of first-generation CD19/HER2 CAR with CD3ζ signaling domain and PD-L1 CCR containing the CD28 costimulatory domain, was constructed and delivered into T cells by pseudotyped lentivirus. The cytokine release, cytotoxicity and proliferation of dual-targeted CAR-T cells were tested in vitro, and their safety and therapeutic efficacy were evaluated using a human tumor xenograft mouse model in vivo. Results The dual-targeted CAR-T cells exerted a similar cytotoxic activity against CD19/HER2 + tumor cells with or without PD-L1 in vitro, however, enhanced cytokine releases and improved proliferative capacity were only observed in the presence of both CD19/HER2 and PD-L1. Importantly, the dual-targeted CAR-T cells displayed no cytotoxicity against PD-L1 + cells alone in the absence of tumor antigen CD19/HER2. In addition, the dual-targeted CAR-T cells preferably destroyed tumor xenografts bearing both CD19/HER2 and PD-L1 , but spared only antigen-positive tumor xenografts without PD-L1 in vivo. Furthermore, PD-L1 CCR also improved the antitumor efficacy of the low-affinity HER2 CAR-T cells against PD-L1 + tumors expressing high levels of HER2. Conclusion Our observations demonstrated that PD-L1 could be used as a universal target antigen for designing CCR, and the dual-targeted CAR-T cells equipped with PD-L1 CCR could be used to reduce the risk of on-target off-tumor toxicity while retaining their potent antitumor efficacy in the treatment of PD-L1 + solid tumors.

The Targeting Effect Of Cetuximab Combined With Pd-L1 Blockade Against Egfr-Expressing Tumors In A Tailored Cd16-Car T-Cell Reporter System

Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56

Chemokine Receptors CCR6 and PD1 Blocking scFv E27 Enhances Anti-EGFR CAR-T Therapeutic Efficacy in a Preclinical Model of Human Non-Small Cell Lung Carcinoma

Enhanced Safety and Antitumor Efficacy of Switchable Dual Chimeric Antigen Receptor-Engineered T Cells against Solid Tumors through a Synthetic Bifunctional PD-L1-Blocking Peptide

Enhancing T Cell Anti-Tumor Efficacy with a PD1-TIGIT Chimeric Immune-Checkpoint Switch Receptor

PD-L1 chimeric costimulatory receptor improves the efficacy of CAR-T cells for PD-L1-positive solid tumors and reduces toxicity in vivo

Refining chimeric antigen receptors via barcoded protein domain combination pooled screening

PD-1 blocking strategy for enhancing the anti-tumor effect of CAR T cells targeted CD105

Development of GPC3 and EGFR-dual-targeting chimeric antigen receptor-T cells for adoptive T cell therapy

Augmenting the Effectiveness of CAR-T Cells by Enhanced Self-Delivery of PD-1-Neutralizing scFv

Retargeted Human Avidin-Car T Cells for Adoptive Immunotherapy of Egfrviii Expressing Gliomas and Their Evaluation Via Optical Imaging

Dual-function Chimeric Antigen Receptor T Cells Targeting C-Met and PD-1 Exhibit Potent Anti-Tumor Efficacy in Solid Tumors.

Development of optimized cytotoxicity assays for assessing the antitumor potential of CAR-T cells

Accurate control of dual-receptor-engineered T cell activity through a bifunctional anti-angiogenic peptide

Advancing CAR T-Cell Therapy: Simultaneously Attack Tumor and Immunosuppressive Cells in the Tumor Microenvironment

Off-the-shelf CAR-NK cells targeting immunogenic cell death marker ERp57 execute robust antitumor activity and have a synergistic effect with ICD inducer oxaliplatin

Targeting PD-L1 in Non-Small Cell Lung Cancer Using CAR T Cells

Noninvasive longitudinal PET/CT imaging of CAR T cells using PSMA reporter gene

Construction of PD1/CD28 Chimeric-Switch Receptor Enhances Anti-Tumor Ability of C-Met CAR-T in Gastric Cancer

Chimeric Antigen Receptor T Cell Targeting to CD19 and CD22 Combined with Anti-PD-1 Antibody Induce High Response in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Optimizing ex vivo CAR-T cell-mediated cytotoxicity assay through multimodality imaging